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Mini-abstract  
Postmastectomy radiotherapy (PMRT) improves breast cancer outcomes but increases 
complications following implant-based breast reconstruction (IBBR). This prospective cohort 
study explored the impact of PMRT on patient-reported outcomes 18-months following IBBR 
showing worse scores in the PMRT group. These results should be discussed with patients to 
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ABSTRACT  
Objective: To explore the impact of postmastectomy radiotherapy (PMRT) on patient-
reported outcomes (PROs) of implant-based breast reconstruction (IBBR) performed with 
and without mesh.  
Summary background data: Post-mastectomy radiotherapy (PMRT) is increasingly given to 
improve breast cancer outcomes but can adversely impact complications following IBBR. 
Little, however, is known about the impact of PMRT on the PROs of IBBR, especially when 
mesh is used.  
Methods: The iBRA (implant Breast Reconstruction evAluation) prospective cohort study 
recruited consecutive women undergoing immediate IBBR from 81 UK breast and plastic 
surgical units. Demographic, operative, oncological and 3-month complication data were 
collected, and patients consented to receive validated PRO questionnaires at 18-months. 
The association between IBBR, PMRT and PROs were investigated using mixed-effects 
regression models adjusted for clinically-relevant confounders and including a random-effect 
to account for potential clustering by center 
Results: 1163 women consented to receive 18-month questionnaires of whom 730 (63%) 
completed it. Patients undergoing PMRT (214 patients) reported worse PROs in three 
BREAST-Q domains: satisfaction with breasts (-6.27 points, p=0.008,95% confidence interval 
(CI)[-10.91,-1.63]), satisfaction with outcome (-7.53 points, p=0.002,CI[-12.20,-2.85]) and 
physical well-being (-6.55 points, p<0.001, CI[-9.43,-3.67]). Overall satisfaction was worse in 
the PMRT group (OR 0.497, p=0.002, CI [0.32, 0.77]). These effects were not ameliorated by 
mesh use.  
Conclusions: PMRT may adversely affect PROs following IBBR irrespective of whether mesh 
is used.  These findings should be discussed with all patients considering IBBR and when 
4 
 
PROs after implant BR and radiotherapy 
indications for PMRT are borderline to enable informed decision-making regarding 
oncological and reconstructive treatment options. 
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INTRODUCTION 
Breast cancer is the most common cancer in women worldwide, with a global incidence of 
2.09 million cases in 20181. Treatment with curative intent involves surgery, often in 
combination with systemic treatment and radiotherapy2. Despite improvements in cancer 
treatment, approximately 40% of all women will receive mastectomy as the surgical 
management of their disease3. Mastectomy may profoundly impact women’s well-being and 
immediate breast reconstruction can improve health-related quality of life (HRQL)4,5.   
Implant-based breast reconstruction (IBBR) is the most commonly performed reconstructive 
procedure in both the UK and US6,7.  It can achieve good cosmetic results and offers patients 
a shorter operation and more rapid recovery than autologous alternatives without donor-site 
morbidity8. Traditionally, IBBR has been a two-stage procedure, involving placement of a 
subpectoral tissue-expander, sequential expansions with saline to reach the final volume and 
subsequent replacement of the expander with a permanent implant. However, the 
introduction of a range of biological (e.g. acellular dermal matrix [ADM]) and synthetic (e.g. 
titanium-coated polypropylene) meshes has led to the development of single-stage direct-to-
implant IBBR techniques. Mesh-assisted sub-pectoral reconstruction involves suturing a mesh 
between the lower edge of the pectoralis muscle and the chest wall, creating an extended 
pocket that can accommodate a fixed-volume implant in one procedure9.  More recently, pre-
pectoral techniques have been introduced. These spare the muscle entirely by wrapping the 
implant in mesh and placing it on top of the pectoralis muscle10. Whilst new IBBR techniques 
have become widely adopted into practice, there is a paucity of high-quality evidence to 
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Post-mastectomy radiotherapy (PMRT) improves breast cancer survival and reduces local 
recurrence12-15, but treatment was traditionally restricted to patients with locally-advanced 
disease (large tumours and/or significant nodal disease).  More recently, evidence has 
emerged to suggest that PMRT may reduce recurrence and improve long-term survival in 
intermediate risk patients, in particular those with one to three positive nodes16. Increasing 
numbers of women are therefore recommended treatment. 
The offer of IBBR in the context of anticipated PMRT remains controversial17,18. Radiotherapy 
may result in skin changes, fibrosis and impaired vascularity and has been shown to be an 
independent risk-factor for complications following IBBR19. In the longer term, capsular 
contracture following PMRT is a significant problem leading to pain and deformity that often 
requires surgery to remove the implant or replace it with autologous tissue20. Using biological 
mesh to provide implant coverage, however, has been shown to reduce levels of 
myofibroblasts, fibroblasts, and other markers of inflammation and fibrosis following PMRT21 
and there is limited evidence to suggest reduced rates of capsular contracture when biological 
mesh is used22.  This may improve outcomes for patients undergoing surgery but there is little 
published literature on the impact of PMRT on patient-reported outcomes (PROs) on IBBR, 
especially in the context of newer mesh-assisted techniques.     
A 2017 systematic review found six studies (593 patients) that evaluated patient satisfaction 
after IBBR and PMRT23. The majority of included studies used non-validated questionnaires 
and the proportion of satisfied patients varied widely24-29. Four studies (575 patients) used the 
validated BREAST-Q questionnaire and demonstrated that patients receiving PMRT reported 
globally worse scores in all domains. None of these studies, however, reported the use of 
newer single-stage mesh-assisted techniques23. More recently, a prospective multicenter 
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cohort study which included 1604 patients receiving both two-stage and single-stage IBBR 
reported reduced satisfaction with breasts associated with radiotherapy (224 irradiated 
patients, 811 non-irradiated) at 1 and 2 years post-operatively19 but did not report details of 
the direct-to-implant techniques used. Smaller retrospective cross-sectional studies have 
produced conflicting evidence regarding the impact of PMRT on PROs following IBBR30-32. With 
the use of both PMRT and IBBR increasing and recent recommendations that reconstruction 
should be offered to all women, even if PMRT is anticipated2, there is an urgent need for high-
quality research to explore the impact of radiotherapy on the outcomes of implant-based 
procedures to help patients make informed decisions about their reconstructive and 
oncological options33. 
The iBRA (implant Breast Reconstruction evAluation) study is a four-phase study aiming to 
inform the feasibility, design, and conduct of a future trial in immediate IBBR11. Phase 2, a UK 
prospective multicenter cohort study, explored the clinical and patient-reported outcomes of 
different approaches to immediate IBBR with and without mesh. The short-term safety 
outcomes have been reported elsewhere9.  Here we report the 18-month PROs of IBBR in 
patients undergoing surgery for malignancy to explore the impact of PMRT on patient 
satisfaction and HRQL and determine whether this is influenced by the use of biological mesh. 
METHODS 
iBRA study design and procedures 
The iBRA study prospectively recruited consecutive women aged 16 years or older undergoing 
immediate IBBR for malignancy or risk-reduction between Feb 1, 2014 and June 30, 2016. All 
UK breast or plastic surgical units performing immediate IBBR were invited to participate via 
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the UK Trainee Collaborative Research Network, the Association of Breast Surgery and the 
British Association of Plastic Reconstructive and Aesthetic Surgeons11. 
Patients at participating centers undergoing IBBR using any technique were eligible for 
inclusion. This included subpectoral reconstructions with and without mesh, and pre-pectoral 
techniques. Patients were excluded if undergoing delayed reconstruction or receiving an 
implant in combination with an autologous flap11.  Patients undergoing neoadjuvant 
chemotherapy or endocrine therapy prior to IBBR were eligible for inclusion. 
Eligible patients were prospectively identified from clinics, multidisciplinary team (MDT) 
meetings, and theatre lists. Demographic, operative, oncological and 3-month complication 
data were collected by the team by clinical or case-note review. Patients who consented to 
participate in the PROs study were sent electronic or postal questionnaires, according to their 
preference, at 3- and 18-months after surgery. The 3-month questionnaire focused on 
satisfaction with information, adjuvant treatment and complications while the 18-month 
questionnaire included BREAST-Q domains relating to satisfaction with outcome and quality 
of life. Reminders were sent after 1 month if no response had been received. Data on PMRT 
were collected by clinical report of treatment recommendations by the MDT and patient self-
report at 3 or 18-months.  Follow-up was complete in December 2017. Anonymized data were 
recorded using REDCap, a secure online database11,34. 
All patients had skin or nipple-sparing mastectomy with immediate IBBR. Procedural details 
were recorded but no restrictions were placed on the techniques (e.g. one or two stage; type 
of implant or expander; types of mesh) used, as this study aimed to explore current practice 
and inform a future trial11. Reconstructive techniques were categorized for analysis as: 
standard two-stage submuscular/subfascial, subpectoral with biological mesh, synthetic 
9 
 
PROs after implant BR and radiotherapy 
mesh, or dermal sling, pre-pectoral, and other. Product choice, implant positioning and use of 
laminar flow, antibiotics and drains were according to local policy or surgeon preference. 
Adjuvant therapies were as recommended by the multidisciplinary team.  
Study governance and consent to participate 
Ethics approval was not required, as the study was defined as service evaluation by the Health 
Research Authority (HRA) decision tool (http://www.hra-decisiontools.org.uk/research/). 
Local audit approval was obtained for each center before commencing study recruitment. 
Clinical and PRO data were collected as recommended by guidelines for best practice35. 
Patients were approached for written consent to receive questionnaires by members of the 
clinical team either in clinic or during their hospital stay, according to local study team 
preference. This was consistent with the methodology used in the UK National Mastectomy 
and Breast Reconstruction Audit (NMBRA)36. Where consent was obtained, patient contact 
details were sent securely to the coordinating center and questionnaires distributed centrally 
to optimize compliance, allow accurate follow-up and minimize missing data11. 
Patient population 
Women from the iBRA cohort who underwent at least one procedure for malignancy (invasive 
breast cancer or ductal carcinoma in situ) and returned the 18-month questionnaire were 
eligible for inclusion in this analysis. Excluded were patients who underwent exclusively risk-
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This study reports the 18-month PROs of IBBR with and without PMRT in patients undergoing 
surgery for malignancy in the iBRA study. 
PROs were assessed using the validated BREAST-Q Post-Operative Reconstructive module 
(version 1). The BREAST-Q is a validated questionnaire robustly developed using Rasch 
methodology for use in a breast reconstruction population and includes six domains: 
satisfaction with breasts; satisfaction with outcome; physical, psychosocial and sexual well-
being37,38. This was selected as it assessed key PRO domains included in the reconstructive 
breast surgery core outcomes set39.  The 18-month questionnaire also included a single-item 
assessment of overall satisfaction outcome on a five-point Likert scale; excellent, very good, 
good, fair and poor, as per the NMBRA36. 
Statistical analysis 
Patients were categorized as having received PMRT (RT group) or not (non-RT group). Patients 
who reported in either the 3-month and/or 18-month questionnaire has having received 
PMRT were included in the RT group. If no patient-reported information was available on 
radiotherapy, patients were classified based on adjuvant therapies recommended at MDT.   
Simple summary statistics were used to describe patient demographics, procedures 
performed to the breast and axilla; postoperative oncological data and MDT decision-making, 
3-month complications and 18-month PROs across the patient groups (responders vs. non-
responders and +/-PMRT). Categorical data were summarized by counts and percentages, and 
continuous data by median, upper and lower quartiles, and range.  The characteristics of 
patients receiving/not receiving PMRT who completed the questionnaire were compared 
using t-tests and chi-squared tests for continuous and categorical variables respectively. 
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Questionnaire responses for the BREAST-Q domains were summed and transformed 
according to the developers’ instructions using the specifically designed Q-Score software40. 
This generated a score from 0 to 100 for each domain where higher scores indicate greater 
patient satisfaction or HRQL37. BREAST-Q scores were treated as continuous variables. For the 
purpose of analysis, the single-item overall outcome score was dichotomized into 
‘excellent/very good’ and ‘good/fair/poor’.   
The effect of radiotherapy on each outcome domain was explored using multivariable mixed-
effects linear and logistic regression models, including a random effect to account for 
potential clustering by center. Models were adjusted for clinically-relevant confounders 
identified by the study steering group based on the literature and clinical expertise. These 
confounders were: age, body mass index (BMI), smoking status, ASA (American Society of 
Anesthesiologists) grade, bilateral surgery, nipple-sparing versus other mastectomy types, 
reconstructive technique (standard two-stage submuscular/subfascial, subpectoral with 
biological mesh, synthetic mesh, or dermal sling, pre-pectoral, and other), 3-month 
complications (infection, implant loss, readmission or reoperation), axillary surgery and 
adjuvant chemotherapy and endocrine therapy.  A complete case analysis was undertaken, 
and robust residual estimates were used to ensure the assumptions of the regression models 
were not violated. The action of biological mesh as an effect modifier in the regression models 
was checked using an interaction term. 
This study was registered (ISRCTN37664281) and is reported according to STROBE 
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The iBRA study recruited 2108 patients from 81 centers between February 1, 2014, and June 
30, 2016, of whom 1693 (80%) underwent surgery for malignancy. The remaining 415 (20%) 
who underwent exclusively risk-reducing surgery were excluded from the analysis.  A further 
56 (3%) patients were excluded as they had no information regarding PMRT. 1164 (71%) of 
the remaining 1637 eligible patients consented to participate in the PROs study and 730 (63%) 
returned the 18-month questionnaire (figure 1).  
Patients consenting to receive PRO questionnaires were demographically representative of 
the cohort of patients with malignancy (Appendix 1). However, patients returning the 
questionnaires were older (median 51.5, interquartile range [IQR] 46-60 vs. 49, IQR 43-57) and 
were less likely to smoke (n=58, 8% vs n=65, 15%) or have experienced major complications 
in particular implant loss at 3-months (n=39, 5% vs n=62, 14%) than non-responders. Full 
cohort demographic details by PRO status and PMRT group are summarized in Appendix 2. 
Participant demographics 
Of the 730 patients completing the 18-month questionnaire, 214 (29%) patients were included 
in the PMRT group; 203 patients who self-reported receipt of radiotherapy at either 3 or 18-
months and 11 patients who did not complete the adjuvant treatment sections of the 
questionnaires but were recommended radiotherapy by the MDT and therefore considered 
to have received it. 516 patients (71%) were not recommended radiotherapy and did not 
report having received treatment so were included in the non-RT group. 
Patients who received PMRT were younger than those who did not, but there was no evidence 
of a difference in BMI or smoking status between the groups (table 1). Patients receiving PMRT 
were more likely to undergo an axillary node clearance (ANC) at the time of reconstruction 
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than patients not undergoing PMRT, but there were no differences regarding the planned type 
of reconstruction (single vs two-stage); technique (use or type of mesh); type of prosthesis 
(tissue expander vs fixed volume implant) or percentage of patients undergoing bilateral 
surgery.  Three-month complication rates were similar between the groups (table 2). Patients 
who underwent PMRT were more likely to have received neoadjuvant chemotherapy, have 
grade 3 cancers, larger tumours and involved lymph nodes (table 3). 
Outcomes 
Table 3 summarizes the 18-month PROs for patients undergoing IBBR by receipt of PMRT. The 
number of responses that were sufficiently complete to be used for analysis were similar for 
each domain, and percentage responses were similar between the radiotherapy groups, 
excepting sexual well-being which was an optional scale and had fewer complete responses 
in the PMRT group (table 4).  Median BREAST-Q scores were lower in the PMRT group across 
all domains. Similar results were observed for the single-item assessment of overall outcome, 
with fewer patients in the PMRT group considering their reconstruction to be ‘excellent’ or 
‘very good’ (table 4).  
Mixed-effects linear regression models were used to evaluate the impact of radiotherapy on 
BREAST-Q scores (table 5). In this analysis, there was evidence that patients receiving PMRT 
reported lower scores in three of the five BREAST-Q domains: satisfaction with breasts, 
satisfaction with outcome and physical well-being, but there was no evidence of a difference 
between groups in scores for sexual or psychosocial well-being. Patients who received 
radiotherapy were less likely to report an ‘excellent’ or ‘very good’ overall outcome than those 
who did not (OR 0.497, p=0.002, CI[0.32, 0.77]).  
14 
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Interaction terms examined the action of biological mesh as an effect modifier in the 
regression models.  There was no evidence that biological mesh modified the association 
between radiotherapy and satisfaction with breasts (interaction coefficient=3.39, p=0.191, 
CI[-1.70-8.48]), satisfaction with outcome (interaction coefficient=4.78, p=0.173, CI[-2.09-
11.65]), psychosocial well-being (interaction coefficient=4.97, p=0.133, CI[-1.52-11.46]), 
physical well-being (interaction coefficient=-0.09, p=0.973, CI[-5.01-4.84]) or overall outcome 
(OR for interaction=1.09, p=0.826, CI[0.52-2.26]). Biological mesh was associated with a 
reduced impact of radiotherapy on sexual well-being (coefficient=13.37, p=0.001, CI[5.61-
21.13]). 
DISCUSSION 
This multicenter prospective cohort study of 730 patients undergoing IBBR with and without 
mesh demonstrates that women receiving PMRT reported worse PROs at 18-months 
following surgery in key HRQL domains: satisfaction with breasts, satisfaction with outcome 
and physical well-being. They were less likely to describe the outcome of their 
reconstruction as ‘excellent’ or ‘very good’ compared with patients who did not receive 
PMRT. These effects were not ameliorated by the use of biological mesh and exceed the 
recently-reported minimum clinically-important difference of 4 points for the BREAST-Q42. 
Furthermore, the scores reported here are similar to those reported by patients undergoing 
mastectomy only in the UK NMBRA36. These findings should be discussed with patients 
considering IBBR in whom PMRT may be indicated or when PMRT recommendations are 
borderline to help them make informed decisions about their reconstructive and oncological 
treatment options, bearing in mind that some women may risk a decrease in satisfaction 
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with their reconstruction, rather than undergoing simple mastectomy, which may be the 
only alternative.   
Several studies19 23,30-32,43-46 have evaluated the impact of PMRT on the patient-reported 
outcomes of IBBR but many of these are small, retrospective and have significant 
methodological limitations including the use of non-validated PROMs24-29 which cannot 
reliably be compared between studies23. Furthermore, much of the evidence to date focuses 
predominantly on traditional two-stage expander-implant IBBR24-26. Evidence regarding the 
impact of PMRT on newer mesh-assisted-techniques is lacking23.  This study provides much 
needed data to support modern reconstructive practice and suggests that consistent with 
the findings of previous work, PMRT adversely affects the PROs of IBBR, even if mesh is 
used. 
Although several studies suggest that acellular dermal matrix may reduce capsular 
contracture following PMRT21,47, the current data do not suggest that this translates into 
improved PROs when biological mesh is used.  Reasons for this are likely complex and may 
indicate that satisfaction is a multidimensional construct that reflects more than objective 
measures such as capsular contracture. Additionally, patients in the current study 
underwent predominantly mesh-assisted subpectoral reconstruction.  Further work is now 
needed to determine if similar results are seen following prepectoral reconstruction as 
emerging data suggests the effects of PMRT may be less marked when the implant is placed 
on top of, rather than under the muscle47,48. 
This is, to our knowledge, the largest prospective study to explore the impact of PMRT on 
single-stage IBBR with and without mesh but has limitations. Firstly, it represents an 
exploratory post-hoc analysis of a subset of patients with malignancy in the iBRA study that 
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was not initially planned and there is the possibility of significant results by chance due to 
multiple testing. The concordance between the current findings and existing published 
data19, however, suggests this is unlikely. 
In addition, this is an observational study and therefore at risk of potential biases such as 
confounding. Although there were no obvious demographic differences between patients 
who consented to receive post-operative questionnaires and those who did not, there were 
clear differences between the patients who completed the questionnaires and non-
responders. Non-responders were more likely to be younger and have experienced major 
complications at 3-months than those who participated, raising the possibility of response 
bias which may have impacted the results. Patients who received PMRT were more likely to 
have more locally-advanced disease than those who were not recommended treatment.  
Attempts were made to adjust for known confounders such as additional oncological 
treatments, but the study may still be subject to bias due to subtler differences between the 
patient groups. As a randomized clinical trial in this context would not be feasible, 
observational data will provide the best possible evidence of the impact on PMRT on the 
PROs of IBBR.   
The study was pragmatically designed to optimize participation and recruitment, but this 
limited our ability to optimize data quality and completeness.  As a complete case analysis 
was performed, the number of patients included in the regression models was limited by 
missing data. There is potential for bias to be introduced due to the missingness and 
interaction term tests for effect modifiers are likely to be underpowered in this analysis.  
Future studies should identify key variables for inclusion and use methods to maximize data 
completion.  Finally, this study assessed PROs 18 months post-operatively.  While these data 
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are important, the effects of PMRT are likely to evolve over time and longer-term outcomes 
would ideally be needed to fully evaluate the impact of PMRT. 
There is growing evidence to suggest that PMRT adversely impacts the early (up to 18-
month) PROs of IBBR. These data should be discussed with patients to help them make 
informed decisions about reconstructive surgery.  Further work is now needed to explore 
whether similar effects are seen with newer prepectoral techniques and to establish if and 
how PROs change over time.  Work is also needed to determine the absolute benefit of 
PMRT.  Current decision making is based on historic data16 and the results of studies such as 
SUPREMO49 are awaited to determine whether PMRT does improve oncological outcomes in 
intermediate risk groups in an era of modern systemic treatment. Other novel methods for 
predicting radiotherapy benefit may also have utility in this group50. Such developments will 
improve decision-making in the future but currently clear communication of the potential 
risks and benefits of both IBBR and PMRT are needed to ensure that patients, in partnership 
with the multidisciplinary healthcare team, make fully-informed decisions regarding their 
breast cancer treatment and reconstructive options. 
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 Figure 1: Patients included in the 18 month patient reported outcome study 
 
 
 
 
 
 
 
 
 
 
 
 
 
